Summary:
- The article reports on successful Phase 3 clinical trial results for plozasiran, an investigational RNA interference (RNAi) therapeutic developed by Arrowhead Pharmaceuticals.
- The drug demonstrated a significant reduction in triglyceride levels and a decreased risk of acute pancreatitis episodes in patients suffering from severe hypertriglyceridemia, marking a major advancement in lipid-lowering medical research.